A treatment has been developed in Australia for leprosy type 2 reaction, a complication in which leprosy sufferers experience fatigue, fever and skin lesions.
The first trials for the treatment will occur for patients in Philippines, Indonesia, Benin, Cote d'Ivoire, Madagascar and the US.
The drug itself is being developed by Melbourne-based not-for-profit pharmaceutical company Medicines Development for Global Health (MDGH).
"This study advances a new therapeutic approach which has the potential to reduce suffering and deliver lasting improvements in patients' quality of life," said Dr Jane Fisher, director of MDGH's clinical operations.
Current treatments of leprosy type 2 reaction are known to have severe side effects.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Feb 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Feb 26
